All In Biotech

Free tool

FAERS Monitor: Paricalcitol

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 207174 or its brand name (Paricalcitol, Paricalcitol). Reports on generic versions are filed under their own applications.

Reports

1,024

Serious

842

82% of reports

Hospitalization

406

Death reported

204

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • calciphylaxis66
  • death66
  • chronic kidney disease57
  • renal failure56
  • pneumonia54
  • drug ineffective45
  • nausea45
  • sepsis41
  • dyspnoea40
  • end stage renal disease38
  • acute kidney injury37
  • renal impairment37
  • hypocalcaemia35
  • pain35
  • asthenia33

Reports by year received

View as table
YearReports
200421
20059
20068
200710
200816
200913
201016
201131
201229
201321
201452
201557
201694
2017110
2018127
2019109
2020101
202148
202239
202352
202424
202521
202616

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,135 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
calciphylaxisSignal66766.6604.347,921
end stage renal diseaseSignal3842.931.41,511
hypocalcaemiaSignal3538.027.51,225
chronic kidney diseaseSignal5715.412.0756
renal impairmentSignal379.16.6258
renal failureSignal568.76.7374
sepsisSignal417.65.6228
acute kidney injurySignal375.03.6114
pneumoniaSignal543.42.692
asthenia331.81.311
death661.61.214
dyspnoea401.51.15
pain351.20.81
nausea451.20.91
drug ineffective450.70.56

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.